Washington Watch
<ѻýҕl class='mpt-top_cat_title_description'>ѻýҕl>
<ѻýҕl>Slippery Slope: Diet Drugs No Help for Heartѻýҕl>
In another edition of the Slippery Slope series examining use of surrogate endpoints in drug approvals, ѻýҕl and the Milwaukee Journal Sentinel find diet drugs are approved without solid evidence of benefits, but with hints of harm.
Apr 19, 2015
<ѻýҕl>FDA Panel Puts Brakes on Anti-PARP Drugѻýҕl>
WASHINGTON -- Approval of a PARP inhibitor for patients with advanced ovarian cancer should await results of an ongoing clinical trial that has the potential to answer questions about the drug's safety and efficacy, according to an FDA advisory committee that voted against immediate approval.
Jun 25, 2014